David A. Siegel Kymera Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 209,100 shares of KYMR stock, worth $6.24 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

209,100

Previous 170,900 22.35%

Holding current value

$6.24 Million

Previous $4.35 Million 93.17%

% of portfolio

0.02%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$22.9 - $43.57 $874,780 - $1.66 Million	38,200 Added 22.35%	209,100 $8.41 Million
Q4 2023 Feb 14, 2024	SELL	$10.97 - $26.84 $193,072 - $472,384	-17,600 Reduced 9.34%	170,900 $4.35 Million
Q3 2023 Nov 14, 2023	BUY	$13.9 - $23.88 $360,010 - $618,492	25,900 Added 15.93%	188,500 $2.62 Million
Q2 2023 Aug 14, 2023	SELL	$22.4 - $34.92 $884,800 - $1.38 Million	-39,500 Reduced 19.54%	162,600 $3.74 Million
Q1 2023 May 15, 2023	BUY	$24.84 - $38.75 $466,992 - $728,500	18,800 Added 10.26%	202,100 $5.99 Million

Q4 2022 Feb 14, 2023	BUY	$19.57 - $30.92 $103,721 - $163,876	5,300 Added 2.98%	183,300 $4.58 Million
Q3 2022 Nov 14, 2022	SELL	$20.91 - $34.27 $1.12 Million - $1.84 Million	-53,700 Reduced 23.18%	178,000 $3.88 Million
Q2 2022 Aug 15, 2022	BUY	$14.13 - $42.55 $2.9 Million - $8.72 Million	204,900 Added 764.55%	231,700 $4.56 Million
Q1 2022 May 16, 2022	BUY	$35.3 - $64.68 $755,419 - $1.38 Million	21,400 Added 396.3%	26,800 $1.13 Million
Q4 2021 Feb 14, 2022	BUY	$49.91 - $65.56 $269,514 - $354,024	5,400 New	5,400 $343,000

Others Institutions Holding KYMR

# of Institutions

164

Shares Held

63.1M

Call Options Held

39.7K

Put Options Held

9.7K

View Full List

About Kymera Therapeutics, Inc.

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $1.63B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

More about KYMR

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account